Skip to main content

Table 1 Patient characteristics

From: The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi

  HBV or HCV coinfected (n.28) HIV + only (n. 281) P value
Age    
Median (IQR) 27.5 (23–30) 27 (23–31) 0.960
WHO Stage N. (%)    
I 17 (63) 211 (75.9) 0.493
II 7 (25.9) 47 (16.9)  
III 3 (11.1) 19 (6.8)  
IV   1 (0.4)  
Week of gestation at ART initiation    
Median (IQR) 27 (24–31) 26 (24–30) 0.576
Duration of ART during pregnancy    
Median days (IQR) 78 (49–92) 70 (44–95) 0.828
ART regimen, N. (%)    
Stavudine/Lamivudine/Nevirapine 15 (53.6) 148 (52.7)  
Zidovudine/Lamivudine/Nevirapine 13 (46.4) 133 (47.3) 0.927
Baseline Hemoglobin (g/dl)    
Median (IQR) 9.8 (9.0-10.9) 10.3 (9.5-11.3) 0.082
Baseline Platelets (x103/mm3)    
Median (IQR) 177 (126–262) 202 (168–249) 0.106
Baseline ALT (IU/ml)    
Median (IQR) 15.5 (12.2-27.1) 12.5 (10–17.8) 0.043
Baseline AST (IU/ml)    
Median (IQR) 28 (23.3-37.1) 25.1 (19.3-34.2) 0.209
Baseline CD4+ cell count/mm3    
Median (IQR) 327 (193–495) 340 (219–494) 0.666
Baseline HIV-RNA log10/ml    
Median (IQR) 3.89 (3.0-4.5) 4.09 (3.4-4.6) 0.297